Fisher Jill A
Harvard Health Policy Rev. 2007 Spring;8(1):61-70.
This paper aims to expand standard conceptions of current ethical issues by discussing pharmaceutical clinical trials in terms of the broader political economy. Specifically, it explores one important characteristic of the political economy in the United States: the trend towards the neoliberalization of health care. First, it provides an overview of neoliberalism and its manifestations in the health care sector. Then, it applies this perspective to pharmaceutical drug development. The paper argues that federal regulation must attend to the context of clinical research to protect human subjects more fully.
本文旨在通过从更广泛的政治经济角度讨论药物临床试验，来拓展对当前伦理问题的标准概念。具体而言，它探讨了美国政治经济的一个重要特征：医疗保健领域的新自由主义化趋势。首先，它概述了新自由主义及其在医疗保健部门的表现。然后，将这一视角应用于药物研发。本文认为，联邦监管必须关注临床研究的背景，以更充分地保护人类受试者。
